Clinical Trial Results:
            A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the renal hemodynamic effects of RLX030 at a dose of 30 μg/kg/day or placebo infused for 24 hours in subjects with chronic heart failure (CHF).
    
|     Summary | |
|     EudraCT number | 2011-001588-37 | 
|     Trial protocol | DE NL PL | 
|     Global completion date | 
                                    20 Dec 2012
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    07 Oct 2016
                             | 
|     First version publication date | 
                                    07 Oct 2016
                             | 
|     Other versions | |
|     Summary report(s) | CRLX030A2202.CTR.01Sept2016 | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
